Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Soligenix, Inc. - Common Stock (NQ:SNGX)

1.270 +0.020 (+1.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Soligenix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
5 Investors Betting Big on Soligenix (SNGX) Stock
SNGX stock is elevating higher after Soligenix released positive results from its HyBryte study. Here are the company's top investors. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Soligenix Targets Psoriasis With New Therapy
Soligenix Targets Psoriasis With New Therapy 
Via News Direct
EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year
Soligenix's IIS study on HyBryte for cutaneous T-cell lymphoma shows 70% success and strong safety profile, with Phase 3 enrollment ongoing. 
Via Benzinga
Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL
Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL 
Via News Direct
EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer
Soligenix opens enrollment for the Phase 3 FLASH2 study of HyBryte in early-stage CTCL, aiming to confirm extended treatment efficacy over 18 weeks. 
Via Benzinga
Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical Needs
Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical Needs 
Via News Direct
Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels
Soligenix starts Phase 2 trial of SGX945 for Behçet's Disease, aiming to enroll 25 patients and report results by mid-2025. Trial includes efficacy assessments. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Levi Strauss Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
7 Top Stocks Under $10: July 2024 Edition
There are more than 2,100 stocks under $10 from which to choose in the market. If you want to find the best, use the Portfolio Grader. 
Via InvestorPlace
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are worth checking out on Wednesday as we break down all of the biggest news worth reading this morning! 
Via InvestorPlace
Why VivoPower International Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket
Via Benzinga
S&P 500 Edges Higher; Indivior Shares Plummet
Via Benzinga
Topics Stocks
Stocks Mixed Following Powell Testimony
The S&P 500 Index and Nasdaq Composite Index are once again extending their record highs, both modestly higher midday. 
Via Talk Markets
Topics Stocks
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Crude Oil Down 1%; Soligenix Shares Surge
Via Benzinga
Nano-Cap Soligenix Stock Surges Over 200% On Tuesday, Here's Why
Soligenix shares surged on heavy volume, following an interim update on the extended Hybryte treatment study. 
Via Benzinga
Why Is uniQure (QURE) Stock Up 51% Today?
UniQure stock is up on Tuesday as QURE investors react to positive clinical trial data for its Huntington’s Disease treatment candidate. 
Via InvestorPlace
Why Is Soligenix (SNGX) Stock Up 296% Today?
Soligenix stock is up on Tuesday with heavy trading of SNGX shares alongside positive clinical trial data from the company. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.